Streamline Health Solutions, Inc.

Hello, and welcome to the Streamline Health Solutions second quarter 2022 earnings conference call. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Jacob Goldberger. Please go ahead, Jacob.

Thank you for joining us for the Corporate Update and Financial Results Review of Streamlined Health Solutions for the second quarter of 2022, which ended July 31st, 2022. As the conference call operator indicated, my name is Jacob Goldberger. Joining me on the call today are T. Green, President and Chief Executive Officer and Chairman of the Board, Ben Stillwell, President and CEO of Evaluator Solutions, Javad Shaikh, President and CEO of AdLead Solutions, and Tom Gibson, Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question and answer session. If anyone participating on today's call does not have a full-text copy of our press release and out-of-views results, you can retrieve it from the company's website at www.streamlinehealth.net or from numerous financial websites. Before we begin with prepared remarks, we want to be sure we are clear for everyone on the record how certain information which may be provided today, as with all of our audience calls, should be viewed. We therefore submit for the record the following statement. Statements made on this conference call that are not historical facts are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These are subject to risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those we may discuss. Please refer to the company's press releases and filings made with the U.S. Securities and Exchange Commission, including our most recent form, 10-K Annual Report, which is on file with the SEC for more information about these risks, uncertainties, and assumptions, and other factors. As always, we are presenting management's current analysis of these items as of today. Participants on this call should take into account these risks when evaluating the topics we will discuss. Please note, Streamline Health is not undertaking any commitment or obligation to publicly revise any such forward-looking statements made today. On today's call, we will discuss non-GAAP financial measures such as adjusted EBITDA and unaudited figures related to our acquisition of equity. Management uses these measures to help provide better insight into our financial performance. However, certain items of income and expense are not included in these measures, so these calculations may differ from those which another entity may utilize in calculating their own non-GAAP measures. To help you compare these amounts on consistent terms, please refer to our website at www.streamlinehealth.net and our earnings release for a reconciliation of such non-GAAP measures to the most comparable GAAP measures. I would now like to turn the call over to T. Green, President and Chief Executive Officer.

Thank you, Jacob, and thank you all for joining us this morning. Following my opening remarks, Ben Stilwell, President and CEO of Evaluator Solutions, and Javad Shaikh, President and CEO of Avalit Solutions, We'll be giving updates on their respective businesses, followed by a financial update from our CFO, Tom Gibson. As a reminder, on August 16, 2021, we acquired Ivy League, and their financial performance will be included in our GAAP results from that date. With that, I'll get started. Beginning with a financial overview of second quarter 2022, we ended the quarter with 5.2% million in new bookings, $4.4 million of which were SAS bookings, at the upper end of our $3 to $5 million quarterly SAS PCV goal. Bookings for the six months ended July 31, 2022, totaled $14 million, $12.5 million of which was attributable to our SAS products. Our strong bookings performance is the result of the significant investments we made into our sales force and attestment to the power of our strong partnership channel. Operating conditions within acute care hospital systems have improved from the peak of the COVID crisis last year. However, headwinds associated with staffing and backlog of projects at hospitals remain. Despite the headwinds, we maintain our expectation that our SAS bookings performance will be on average in the $3 to $5 million per quarter throughout fiscal 2022. Our bookings pace has improved. However, we believe in a normalized environment, our bookings performance would accelerate. Given the pace of our bookings during the first half of this quarter, we wanted to share a new metric to provide additional insight on the growth in our business. As of July 31st, our booked SAS annual contract value totaled $14.3 million. As a reminder, our GAAP SAS revenue in fiscal 2021 was $8.1 million. Our CFO, Tom Gibson, will provide additional details related to this metric and the timing of revenue associated with our bookings during his portion of today's call. But please note that contracts only impact recognized revenue once the software is live. Moving now to our GAAP consolidated financial results for the three months ended July 31st. Total GAAP revenue for the second quarter of 2022 was $6 million. 109% increase from the second quarter of 2021. Notably, our SAS revenue grew 138% year over year. Recurring revenue accounted for 71% of total revenue in Q2 2022 compared to 84% during the second quarter of 2021. On a pro forma basis, total revenue for Q2 2022 increased 19% from the prior year. VAST revenue grew 11%. Second quarter 2022 adjusted EBITDA was a loss of $1.1 million compared to an adjusted EBITDA loss of $800,000 in second quarter of 2021. As of July 31st, 2022, we had $5.9 million of cash on hand and $10 million term loan. Our cap table remains clean with only one class of common stock. Tom Gibson, our CFO, will provide additional details about our financials during his prepared remarks. Both Avalit and Evaluator continue to improve the innovation and service functions of their respective businesses. Avalit is driving significant bookings with new and existing clients through its Cerner relationship, and the business is maturing rapidly under Javad's leadership. Evaluator has made rapid progress as well. Over the past nine months, we have made investments to extend Evaluator's reach to the professional fee environment as our customers have asked for a consistent coding environment across all claims. Evaluator now offers inpatient, outpatient, and professional fee modules. Both new and existing clients purchased the Pro Fee Evaluator module during the second quarter of 2022. Before I turn the call over to Ben, I want to acknowledge the progress we have made in building a successful sales structure within our company. As we have discussed, our model is innovation plus service equals growth. We have made great progress within our innovation and service functions. Beginning in the second half of last year and culminating with the addition of Amy Severo, Evaluator CRO, we made significant investments into our growth functions. This investment in growth was key as the hospital system software market requires C-suite relationships to effectively move contracts through to execution. Today, we believe we have a powerful growth function. One, CRO Amy Severo, three seasoned business development personnel to manage channel relationships, three inside sales personnel that generate leads and push promotions, six direct regional sales personnel that have C-suite relationships inside hospitals in their regions, and five marketing and advertising personnel. The team has a sales administrator coordinate all these activities along with the demonstration personnel. We have worked hard over the last year to build this structure and make the right investments. Today, 18% of our total headcount is dedicated to growth. We believe the current investment level is sufficient to meet or exceed our bookings goals. I'll now turn the call over to Ben to provide an update regarding evaluator.

Ben? Thank you, T, and good morning. We were pleased to close several significant evaluator bookings during our second quarter, one of which was the largest ever evaluator deal by ACV, and another which represented our first existing client expanding into our new professional fee module. There's no doubt that our sales success is a result of providing white glove client service, investing into product innovation, and the build out of our growth team, which T referenced. We continue to meet with many of our existing and potential clients on site. During these meetings, our clients and prospects describe numerous headwinds from the backlog of IT projects to turnover of both clinical and professional staff. I believe our key to success will be approaching these healthcare organizations with solutions that reduce or eliminate the effort required to achieve the financial outcomes our software enables. One way we do that today is with our Client Success Program, which includes monthly conversations on how we can improve the use of the software, regular client roundtables to discuss key issues, and quarterly leadership meetings to fit our product into the bigger picture. We consistently hear that our Client Success Program is a primary differentiator between us and the rest of the vendor landscape, As a result, our existing clients are seeing significant financial impact. We recently published a white paper for Cooper University Hospital on our website that illustrates this impact. Cooper is a great example of a client who gets creative, pushes us, and ultimately enables better outcomes. Still, potential clients need help getting the same value as Cooper, and during the sales process, they often express concern with their ability to achieve value quickly given staffing challenges. To address these needs, we are expanding the client success offering to include what we are calling the evaluator concierge, which helps to shift the speed to value curve to the left. These concierges start off fully integrated with the client's team, allowing us to quickly learn about and react to any potential pain points. These concierges will provide us the insights we need to speed adoption and maximize client resources. We also continue to execute on evaluator product innovation, On our last call, I mentioned that the pro-fee module of Evaluator had entered its beta phase. The pro-fee module helped contribute to bookings this quarter and was a component of the largest ever Evaluator deal. Many of our current clients are interested in complementing their inpatient and outpatient suite of products with our pro-fee module, and we anticipate it'll be a contributor to our bookings going forward. It was a very rewarding quarter, and I thank our associates, clients, and prospects for making it possible. I look forward to sharing additional success and updates on our next call, and I will now turn the call over to President and CEO of Avalede, Javad Shaikh, to provide a business update for Avalede. Javad?

Thank you, Ben, and good morning to you all. Unlike Evaluator, Avalede has investments required on the innovation and service side to deliver world-class technology and client satisfaction. We have not finalized our scorecard for our clients to observe the ROI delivered by our products. We continue to make significant improvements to our tools to ensure they are ready for the enterprise-level growth we anticipate in the coming years. With that said, the growth opportunity lies in expanding our footprint within existing contracted clients and an exhaustive list of opportunities through our large channel partner, Cerner. We have successfully worked with Cerner to build our existing client base and pipeline. Within our sales process, we utilize RevID's proven ROI and referenceable client relationships to drive bookings and revenue. Just like Evaluator, we see opportunities opening within our direct and channel partner pipeline as the impact from COVID retreats. During the second quarter, we closed our first successful booking with one of the largest hospital systems based primarily in the Southwestern United States. This initial booking came on the heels of a rigorous nine-month pilot program and resulted in a contract for our Compare product across approximately 5% of its total facilities. Again, the initial booking was one product compared across a minor portion of the entire hospital system base. The Southwestern United States hospital system has the potential of being larger than the Tennessee hospital system that is now generating over $5 million of annualized top-line SAS revenue for our business. I will now turn the call over to our CFO, Tom Gibson, to review our financial results in more detail. Tom?

Thank you, Javad. As T mentioned in his opening remarks, we acquired Avalib on August 16th, 2021. All operations of Avalib are included in our reported GAAP numbers from that date. We also provide pro forma numbers that assume we owned Avalib from the beginning of the prior year period. Total gap revenues for the second quarter of fiscal 2022 were $6 million, a 109% increase over the comparable period of last year. $2.5 million was attributable to Adelaide. For the six months into July 31, 2022, total gap revenue increased 105% to $11.9 million. $5 million of the increase was attributable to the acquisition of Avalib. SAS GAAP revenue increased $1.8 million or approximately 138% compared to the same quarter a year ago. And for the six months ended July 31, 2022, SAS GAAP revenue increased $3.5 million or approximately Total revenues for the second quarter of fiscal 2022 and year to date were $6 million and $11.9 million, compared with pro forma revenues of $5.1 million and $10.5 million, respectively, for the year-ago periods. Moving back to our GAAP numbers, second quarter 2022 operating expenses totaled $8.6 million compared to $5.2 million for the prior year period. $3.2 million of the increase was related to the acquisition of Avalie. The company increased its spend in innovation during the quarter by approximately $500,000. This increased spend was related to the acquisition of Avalede and certain costs to deliver several critical product improvements. Further, the company saw the full impact of its investments in the quarter for its reformed sales function and travel resumed to nearly pre-COVID levels. For the six months ended July 31, 2022, Total operating expenses were $17.8 million as compared to $10.7 million during the prior year period. $6.4 million of that increase was attributable to the acquisition of Abilene. Loss from continuing operations for the three months ended July 31, 2022 was $3.3 million. compared to loss from continuing operations of $100,000 for the three months ended July 31, 2021. Loss from continuing operations for the three months ended July 31, 2022 included $49,000 of acquisition related costs and $425,000 related to evaluation adjustment on acquisition related liabilities. Loss from operations for the quarter ended July 31, 2021 included $2.3 million of income associated with the forgiveness of the company's PPP loan. For the six months ended July 31, 2022, loss from continuing operations was $6.1 million compared to a loss from continuing operations of $2.5 million for the six months ended July 31, 2021. Loss from continuing operations for the first half of fiscal 2022 included $139,000 of acquisition-related costs, while loss from continuing operations for the first half of 2021 included $0.8 million of acquisition-related costs and $2.3 million of income associated with forgiveness of the company's PPP loan. Adjusted EBITDA for the second quarter of fiscal 2022 was a loss of $1.1 million compared to an adjusted EBITDA loss of $800,000 in the same quarter of fiscal 2021. The higher adjusted EBITDA loss can be explained by investments made by the company in innovation and sales during the first six months of fiscal 2022 when compared to fiscal 2021. Moving to the balance sheet, as of July 31, 2022, we had $5.9 million of cash on hand compared to $9.9 million at January 31, 2022. The company completed the acquisition of Avali using approximately $12.5 million of cash and $6.5 million of restricted stock at closing. Under the acquisition agreement, the company will provide additional consideration on each of the next two 12-monthly anniversaries of the closing date. These will be paid to the sellers in cash and stock and are valued on the balance sheet at approximately $8.8 million. These liabilities are referred to as acquisition earn-out liabilities and are an estimate of the present value of future amounts that will be paid in cash and restricted common stock upon the anniversary dates of the acquisition. Subsequent to the closing of the Abilete acquisition, we entered into a five-year, $10 million term loan with Bridge Bank. There is no repayment of the term loan required in the first year following close. $500,000 is required in the second year following close, which equates to $41,667 monthly beginning in August 2022. The company maintains this position that the uncertainty related to the effects of the novel coronavirus Impacts on the healthcare market prevents us from providing detailed guidance. We continue to target an average go-forward SAS bookings pace of $3 to $5 million of TCV per quarter for 2022. And as a reminder, to date, we have closed $12.5 million of SAS TCV. As T mentioned, we are introducing a new metric that provides each of an annualized contract value for agreements that are being recognized into revenue, as well as bookings that have not implemented. We will refer to this figure as our Booked SAS ACV, where ACV stands for annual contract value. We believe Booked SAS ACV will provide a proxy for our annual recognized revenue as if all executed contracts are live and recognizing revenue. Please note that the recognition of revenue from our signed contracts is subject to the timing of implementations. Implementations may sometimes be delayed by customers due to competing projects or be timed after a larger implementation of another system. Generally, we have recognized revenue from evaluator projects in 90 to 120 days from contract signing, while AVA lead products, due to the complexity of implementation, may be 120 to 150 days. As Tee remarked, our book SAS ACV as of July 31, 2022, was $14.3 million and approximately $3.2 million of that book SAS ACV has not been implemented. We remain focused on continued growth of SAS revenue. On its current cost structure, we believe our overall business will achieve break even at a booked SAS ACV of $17 million. We expect that we will reach this level of bookings in Q3 or Q4 2022 and have this revenue fully implemented by Q3 or Q4 of 2023. The company is realizing incremental SAS gross margins above 80%. Since I joined the company in September 2018, we have not experienced our current level of growth nor the near-term visibility to cash generations. I am proud of the progress we have made to date and want to commend our staff on our recent success. That concludes my review. I will now turn the call back to T. Green for his closing remarks.

T? Thank you, Tom. We continue to enable health care providers to proactively address revenue leakage and improve financial performance and have taken major steps forward to drive diversified recurring revenue streams, and better position our company for growth and to deliver significant shareholder value over the long term. The integration of Avalit into the Streamline Health family has been smooth, and the product innovation and dedication to our healthcare partners remains a priority and strength across the company. Before we begin our Q&A session, I'd like to thank the entire Streamline team Once again, for all their hard work and dedication, their contributions are essential for us to support our healthcare providing clients and ensure they have the necessary tools to free up time and resources to provide quality care for the communities they serve. Thank you all for your support of streamlined health and our vision. Now I'd like to open the call up to your questions, operator.

Thank you, and I'll be conducting a question and answer session. If you'd like to be placed in the question queue, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you'd like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing star 1. One moment, please, while we poll for questions. Our first question today is coming from Matt Hewitt from Craig Hallam Capital Group. Your line is now live.

Good morning. Congratulations on the progress, and thank you for taking the questions. Maybe the first one for me, and you touched on this a little bit in your prepared remarks, but regarding the hospital spending environment, obviously as we're coming out of pandemic, you're able to get in and meet with the customers, meet with the hospital administration, but they still are facing a pain point from a staffing perspective, and I'm curious how those conversations are going given the that your products actually solve some of that problem for them? Are you finding the customers more receptive because your technology helps them on that front?

Yeah, Matt. T here. Thanks for the question. Yeah, we're clearly seeing health systems, I guess, get back to – I hate to use the word normalcy, but getting back to their – typical work in fashion of making clinical financial administrative decisions and how they run their health system versus everything focused on COVID and nothing else mattered, which was what they had to do for several years. So now that that is thawed, the CEOs and CFOs are definitely looking towards, okay, where can I make improvements in my business now? And it's probably not necessarily building new facilities and inflationary environments we're in so that's probably not the right swim lane for them the second thing is everybody wants the the clinical for care care care but some of these clinical applications although much needed some of them are are going to have to wait because of the financial scenarios these health systems find them in so Looking at revenue cycle technology is the logical next place for CFOs to look, is how do we improve financial performance? And so clearly things like Evaluator and RevID from Avalib fit right in that discussion. Then the second thing they look at is, well, if you look at all my auditors and billing personnel, They left. I don't know what percent. It'll be interesting to see some of the studies coming out, but a large percent of the people left the hospital workforce that used to work in what you would consider the revenue cycle area. They're not coming back. These health systems are not only having a hard time staffing nurses, they're having a tremendous time staffing their revenue cycle business. They have to look for innovation. I think that's where streamlined is in a really neat place, we believe, going forward.

That's great and really helpful. Thank you. Maybe a follow-up regarding the new Southwest Health System win in the quarter. You know, thank you for the color on that. I'm curious. I mean, at 5% or I'm sorry, what was it, five hospitals with the potential to expand much larger than that in the future, Is there set milestones or criteria that would allow you to expand into additional hospitals within that system, or how should we be thinking about that contract?

Yeah, you know, I'll take this, and I'll let Javad and Tom maybe chime in as well. But, you know, there are – And some of this would be our confidential to our technology and why things like Rev ID are so valuable. But, you know, when you think about our model, innovation plus service equals growth, if we don't get the innovation correct in the pilot, you know, there's no way we're going to move to the next step. And so that's the focus with these is get the innovation correctly, prove that it can scale in enterprises. And then make sure the service side, make sure that we're delivering what is Javad said. We're still working. We know there's tremendous ROI, but we're still working on those, getting it advanced to say on the evaluator side so that we can prove every month, every quarter that we're hitting the march on the ROI side. And that's where the service component comes in. We do those two things, Matt, we know we're going to grow. So that's where we're focused.

Got it. And then maybe a last one for me and I'll hop back into the queue, but As things are thawing up and you're seeing hospitals refocusing their energy on just running the business versus kind of treating COVID patients, could you talk a little bit about the pipeline and how that has built over maybe the first half of the year and how you expect that to kind of play out over the back half? Thank you.

Yeah, why don't we do this? Hey, Ben, why don't you take the evaluator just so that they, you know, investors here from you guys in Javad, you take the Avalit side because they're both very exciting.

Yeah. So I think what we've seen kind of built throughout this year as we've built out the sales team, Amy obviously coming on board, we've sort of shifted how we're presenting ourselves. You heard me mention the client success program. I think that really we've started to lean into that because of the staffing challenges, because of the desire to get more out of less kind of concept and that program really helps enable that. So, as we've pushed that more and more and kind of helped overcome some of the objections that we normally hear, which are, you know, budget and staffing, we've seen our ability to talk to those kind of improve, and so I think the pipeline has built up as a result. And then we've had a lot of delivery on the innovation side, on the product side, that's also helped increase productivity and things like that.

Yeah, and just to kind of add on to that, our focus has continued to be obviously on innovation, as T mentioned, but our pipeline has continued to focus on obviously growing within our existing customers, which has been going well, and also expanding with our Cerner partnership as well, too. But the goal is really to stay patient and continue to invest in that innovation as we're continuing to build these relationships and continuing to build the pipelines So everything kind of lines up with the I plus S plus G strategy as well too. So we're continuing to focus on those partners and we're getting good pipeline growth or steady pipeline growth with that as we continue to focus on our R&D.

That's great. Thank you very much.

Thank you. Next question is coming from Kyle Bowser from Lake Street Capital Markets. Your line is now live.

Great. Hi, everyone. Great results today and thanks for the updates. So we're clearly seeing an expansion of new clients being layered into the business from all the recent contract win announcements and the recurring revenue metric of 71% versus 84% a year ago. And it sounds like the investments into the evaluator commercial team is really driving a lot of this, presumably. you know, with the existing relationships that the sales reps have. But just wanted to get a sense of kind of the magnitude of some of the other drivers. You've talked a little bit about this, but you can talk more about, you know, other drivers such as hospital referrals. Are we seeing that or even the rollout of your services to new facilities within growing hospital systems that are consolidating or even, hospitals that have kind of been in a holding pattern in your pipeline and are now kind of moving forward? Just kind of curious the magnitude of each of these other drivers.

Yeah, thanks, Kyle. The macro side of it is that there's two, I guess, major things happening right now in the health systems. You know, one is the CFOs recognizing that two and a half years of COVID has taken a significant financial impact on the business. And so they have to right the ship in many areas. And that leads to revenue cycle improvements. And so that's, if you go in any health system in the country, that's probably one of the top conversations. The second is staffing. And so It's one thing to say, okay, here's our revenue cycle challenges, and here's what we've got to do to right the ship and to get back to financial help. The second part of that is you would normally go out and historically ramp your billing, your collections, your auditing, and you can overcome some weakness just through sheer human effort. The problem today is that human effort is not coming back. And that's – so those are two major things happening in health systems today that are going to require that CFOs look to technologies, innovation that can improve financial performance, but also you can do it without having – that can replace headcount. And because of our pre-built technology, it does both. It improves financial performance. It also reduces the need for bodies to be in that business. And to me, yes, we have to staff our growth teams. Yes, we have to have great strategies for marketing and BD. But those two micro trends right there are your drivers for the next several years, in my opinion.

I appreciate that. Clearly the value prop is the highest it's ever been based on kind of what you just said, T. Appreciate that. And then I guess regarding the pro fee module, it's great to see that it's already being deployed within new and existing clients. I'm just kind of curious to the extent you can estimate maybe percentage or number, you know, how many, of your current clients do you think are kind of high probability targets for adding on this, no, this new, uh, pro fee module?

Hey Ben, why don't you take that and also cover not just current, but what your pipeline shows for pro fee?

Yeah. So I think, um, I'd say it's about half of our current clients are, are ideal candidates at the moment. I think the, the main, um, signal to us is whether or not that professional practice is in the same revenue cycle function or if it's something they recently acquired and is not integrated with the hospital revenue cycle function. And so you see it done both ways, and we're probably going to be a lot more successful in the initial outset if those two groups are together, because then you're benefiting from common coding practices, from reporting, et cetera. As far as the pipeline, I think we're seeing the the largest deal that we announced a little bit earlier, we were able to do that because we had professional fee. It was a need for them in order to work with us. And so we're seeing there's a number of opportunities that we've talked to in the past who kind of said, this is great, but we were trying to find something that goes across the entire enterprise, and now we have that ability. And so I think we'll see that more or less sold with the vast majority of our net new deals going forward I'm still dependent on that, you know, the revenue cycles being integrated. But, yeah, it's kind of – it's opening up doors for us, I would say.

Great. Appreciate that. And then just lastly, kind of a similar question on the Avalit side of the business, kind of what are the key drivers for, in particular, the PHR migration? So is it just old systems finally getting upgraded or – consolidation in the space, you know, where we're switching systems that the targeted companies were using to the ones that the acquirers are using, or is it just kind of the natural share dynamics playing out between EHR companies? I'm just trying to kind of get a sense of what's also driving the contracts, like the one announced in early August, I think on August 1st. Thank you.

Yeah, hey, Javad, why don't you... walk out through the Cerner relationship, but also kind of what the technologies comparing RevID can do and, you know, what we've seen in Epic and Meditech and others.

Yeah, definitely. And I think, you know, our starting point in our history has been kind of conversions or EHR migrations, and that continues to play a role in kind of driving and getting engagement with some of these clients, including this big one as well, too. but it's kind of a twofold step. We're going to continue to do those. We're continuing partnering with Cerner to do those as well too. But as we're getting more clients under our belt and being able to clearly document the ROI and the value that our clients are getting, we're able to use that to go back to other clients that are already maybe live on our EHR or have been for a long period of time. So kind of growing it that way as well too. So it's both a conversion EHR migration as well as expanding naturally and telling the ROI and the value our clients are getting and spreading that word to more future clients.

That makes sense. Great. Thanks for taking my questions, and congrats on the great update today.

Thank you, Kyle.

Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over for any further or closing comments.

Thank you all again for your interest and support of Streamlined Health. If you have any additional questions or need more information, please contact me at jacob.goldberger at streamlinedhealth.net. We look forward to speaking with you all again when we discuss our third quarter fiscal year 2022 performance. Good day.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.